Stage IIIB Cutaneous Melanoma AJCC v7 Recruiting Phase 1 Trials for Aldesleukin (DB00041)

IndicationStatusPhase
DBCOND0091048 (Stage IIIB Cutaneous Melanoma AJCC v7)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01955460Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV MelanomaTreatment